PRINCETON, N.J.–Bristol Myers Squibb (NYSE: BMY) has reported preliminary Phase 3 clinical trial results showing improvements in hallucinations, delusions and overall disease severity among patients receiving KarXT for psychosis associated with Alzheimer’s disease.
The findings, presented at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference in Boston, represent the first clinical data released from the company’s ongoing Phase 3 ADEPT program.
The results come from the 12-week open-label treatment period of the ADEPT-1 study and the 52-week open-label extension study, ADEPT-3. Both studies evaluated xanomeline and trospium chloride, collectively known as KarXT.
According to Bristol Myers Squibb, patients receiving KarXT demonstrated improvements in clinician-assessed hallucination and delusion scores, along with reductions in overall disease severity. The treatment was generally well tolerated across both studies, with no new safety concerns identified.
In ADEPT-1, 320 patients had enrolled at the time of analysis, with 273 participants, or 85.3%, completing the 12-week open-label treatment period.
Patients experienced an average 12-point reduction from a baseline score of 14.4 on the Neuropsychiatric Inventory-Clinician Hallucinations and Delusions (NPI-C H+D) scale. The Clinical Global Impression-Severity (CGI-S) score also improved, declining by an average of 1.9 points from a baseline of 4.5.
Treatment-emergent adverse events were reported in 56.6% of participants, while 5% experienced serious adverse events. Approximately 4.4% discontinued treatment because of adverse events.
The ADEPT-3 study, which evaluates long-term safety and tolerability among patients completing earlier ADEPT trials, enrolled 401 participants at the time of analysis. Of those, 273 patients, or 68.1%, completed the 52-week treatment period.
In the extension study, patients experienced an average 5.1-point reduction from an open-label baseline of 8.9 on the NPI-C H+D scale. CGI-S scores declined by an average of 0.8 points from a baseline of 3.4.
Adverse events occurred in 65.1% of participants, with serious adverse events reported in 7.7%. Approximately 4.7% discontinued treatment because of adverse events.
“Hallucinations and delusions are particularly challenging aspects of Alzheimer’s disease and have a significant impact on people living with the disease, as well as their families and caregivers,” said Jeffrey L. Cummings, MD, ScD, Joy Chambers-Grundy Professor of Brain Science and Director of the Chambers-Grundy Center for Transformative Neuroscience at the Kirk Kerkorian School of Medicine at the University of Nevada, Las Vegas.
“These preliminary findings further our understanding of the possible impact of KarXT in this setting as we work to uncover new ways to help alleviate the added burden of psychosis for patients and families living with this devastating condition.”
Cristian Massacesi, MD, Executive Vice President, Chief Medical Officer and Head of Development at Bristol Myers Squibb, said the studies are examining different aspects of KarXT treatment, including short-term clinical responses and longer-term safety.
“ADEPT-1 and ADEPT-3 are designed to answer two different, important questions. The open-label period of ADEPT-1 provides an initial look at how patients respond to KarXT over 12 weeks, while ADEPT-3 is evaluating the long-term safety and tolerability of KarXT over 52 weeks,” Massacesi said.
“We believe the improvement in hallucinations and delusion scores in ADEPT-1 and the long-term safety and tolerability findings shown in ADEPT-3 are encouraging as we await results from the double-blind periods of the ADEPT program. We look forward to sharing additional results as the program advances.”
The company emphasized that the findings are preliminary and based on descriptive analyses. Patients who remained in the studies at the time of the data cutoff were excluded from the reported analyses.
Because the findings come from open-label treatment periods, they do not establish how KarXT performs compared with a placebo or other treatments. Results from the double-blind portions of the ADEPT program remain blinded, and the trials are continuing.
The ADEPT program is investigating KarXT as a potential treatment for psychosis associated with Alzheimer’s disease, a condition characterized by hallucinations and delusions that can complicate patient care and increase the burden on families and caregivers.
Bristol Myers Squibb said additional clinical results will be released as the studies progress.


